Trial Profile
Experience With H.P. Acthar Gel Treatment of Patients With Nephrotic Syndrome/Proteinuria Due to Various Etiologies and Its Effect on Podocyte Function
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 03 Feb 2022
Price :
$35
*
At a glance
- Drugs Corticotropin (Primary)
- Indications Nephrotic syndrome; Proteinuria
- Focus Therapeutic Use
- Acronyms Acthar
- 04 Feb 2020 Planned End Date changed from 31 Dec 2019 to 31 Dec 2021.
- 04 Feb 2020 Planned primary completion date changed from 31 Dec 2019 to 31 Dec 2021.
- 30 Aug 2018 New trial record